LipoScience (LPDX +0.6%) moves up after Piper Jaffray initiates the shares with an Overweight and a $15.00 price target. Piper notes that ongoing traction converting its LDL-C patient monitoring assays to LDL-P and represents a potential $330M annual revenue run-rate, which would exceed both its top and bottom-line projections. Separately, Barclay's and UBS also initiated coverage with an Overweight and Buy, respectively.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs